The global shortfall of dementia specialists represents one of the most urgent bottlenecks in neurodegenerative care — millions of patients wait months or years for a diagnosis that meaningfully changes treatment trajectories. A framework that could replicate specialist-level reasoning at scale, without proportionally scaling the specialist workforce, would fundamentally alter how and when dementia is caught and managed.
Published in Nature Aging, this Perspective piece outlines a conceptual architecture for agentic AI systems designed to augment clinical workflows across the full spectrum of neurodegenerative disease. Unlike passive decision-support tools that flag anomalies, agentic AI refers to systems capable of autonomous, multi-step reasoning — integrating neuroimaging, biomarker panels, longitudinal clinical notes, genetic data, and patient-reported outcomes into continuously updated patient models. The authors propose a human-AI collaborative loop in which the system learns dynamically from new patient data, refining diagnostic confidence over time rather than relying on static training sets. The explicit goal is democratizing specialist-level dementia care for populations underserved by current geography or healthcare infrastructure.
The proposal sits at an important inflection point. Large language models and multimodal AI architectures have recently demonstrated meaningful performance in medical reasoning tasks, but translating that capability into clinical-grade, regulatory-compliant, continuously learning systems remains largely unsolved. The agentic framing is conceptually ambitious — autonomous reasoning across heterogeneous patient data raises substantial questions around explainability, liability, and failure modes in vulnerable populations with cognitive impairment. This is a Perspective, not an empirical study, so the claims rest on expert vision rather than trial evidence. Its real value lies in establishing a design philosophy and research agenda. For the longevity and brain-health community, the practical implication is that AI-assisted early detection of neurodegeneration — potentially years before symptom onset — could become a realistic near-term target if these architectural principles translate into validated clinical tools.
